Skip to main content

Advertisement

Table 3 Changes within groups in primary and secondary outcome measures0

From: The effectiveness of the Austrian disease management programme for type 2 diabetes: a cluster-randomised controlled trial

Reduction of Intervention Control
  n1 mean2 95% CI p-value3 n1 mean 95% CI p-value3
primary outcome measure
HbA1c (%) 590 0.41 [0.32; 0.50] <0.0001 754 0.28 [0.21; 0.35] <0.0001
secondary outcome measures
Creatinine (μmol/l) 586 -0.88 [-2.65; 0.88] 0.165 739 0.88 [-0.88; 2.65] 0.504
Triglycerides (mmol/l) 585 0.15 [0.02; 0.27] 0.021 736 0.09 [0.00; 0.17] 0.046
Cholesterol (mmol/l) 585 0.06 [-0.01; 0.14] 0.112 736 0.01 [-0.06; 0.07] 0.797
HDL (mmol/l) 585 -0.02 [-0.04; -0.01] 0.011 736 -0.01 [-0.03; 0.01] 0.209
LDL (mmol/l) 585 -0.01 [-0.08; 0.07] 0.864 736 0.04 [-0.02; 0.10] 0.161
RR systolic (mmHg) 561 2.49 [1.03; 3.94] 0.001 691 0.68 [-0.46; 1.83] 0.241
RR diastolic (mmHg) 561 1.16 [0.35; 1.98] 0.005 691 0.61 [-0.08; 1.30] 0.084
BMI 568 0.31 [0.17; 0.44] <0.001 695 0.04 [-0.09; 0.16] 0.540
  1. 0 Reduction is shown as positive number.
  2. 1 n per protocol
  3. 2 intention to treat
  4. 3 paired T-Test